T. Rowe Price Associates
HUMA icon

T. Rowe Price Associates’s Humacyte HUMA Stock Holding History

T. Rowe Price Associates’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69K Buy
112,172
+36,155
+48% +$37.6K ﹤0.01% 3045
2025
Q4 		$73K Buy
76,017
+13,175
+21% +$18.7K ﹤0.01% 2990
2025
Q3 		$110K Hold
62,842
– – ﹤0.01% 2905
2025
Q2 		$132K Buy
62,842
+25,252
+67% +$48.5K ﹤0.01% 2837
2025
Q1 		$65K Buy
37,590
+3,720
+11% +$14K ﹤0.01% 2895
2024
Q4 		$172K Buy
33,870
+5,801
+21% +$28.7K ﹤0.01% 2740
2024
Q3 		$153K Hold
28,069
– – ﹤0.01% 2740
2024
Q2 		$135K Buy
28,069
+12,216
+77% +$63.6K ﹤0.01% 2694
2024
Q1 		$50K Buy
15,853
+405
+3% +$1.36K ﹤0.01% 2873
2023
Q4 		$44K Buy
15,448
+1,512
+11% +$3.88K ﹤0.01% 2827
2023
Q3 		$41K Buy
13,936
+1,932
+16% +$6.39K ﹤0.01% 2798
2023
Q2 		$35K Hold
12,004
– – ﹤0.01% 2840
2023
Q1 		$38K Buy
+12,004
New +$34.1K ﹤0.01% 2816

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

T. Rowe Price Associates's HUMA Position: Q1 2026 in Review

T. Rowe Price Associates increased its Humacyte (HUMA) stake by 48% in Q1 2026, buying an estimated $37.6K and bringing the position to 112,172 shares worth $69K. The position accounts for ﹤0.01% of the portfolio, ranked #3045.

T. Rowe Price Associates first reported a position in HUMA in Q1 2023 and has held it in 13 quarters since. The position peaked at $172K in Q4 2024. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • T. Rowe Price Associates held 112,172 shares of Humacyte worth $69K as of Q1 2026.
  • T. Rowe Price Associates bought 36,155 Humacyte shares in Q1 2026, an estimated $37.6K.
  • Humacyte made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3045 holding.
  • T. Rowe Price Associates first reported a position in Humacyte in Q1 2023 and has held it in 13 quarters since.
  • T. Rowe Price Associates's Humacyte position peaked at $172K in Q4 2024.
  • 158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.